851 | TITANium: A MULTICENTER PHASE 1/2 STUDY OF AZD5492, A FIRST‐IN‐CLASS CD8‐GUIDED TRISPECIFIC T‐CELL ENGAGER, IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL MALIGNANCIES

Documenti analoghi

• 831 | A PHASE 1, MULTICENTER, FIRST‐IN‐HUMAN TRIAL OF GCC2005, AN ALLOGENEIC CAR‐NK CELL THERAPY TARGETING CD5, IN PATIENTS WITH RELAPSED/REFRACTORY NK AND T‐CELL MALIGNANCIES
  di: W. S. Kim, et al.
  Pubblicazione: (2025)
• 838 | A PHASE 1 TRIAL OF NX‐2127, A FIRST‐IN‐CLASS BTK DUAL‐TARGETED PROTEIN DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL MALIGNANCIES
  di: A. Danilov, et al.
  Pubblicazione: (2025)
• 317 | MOLECULAR SUBTYPE‐GUIDED R‐MINE+X REGIMEN IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: A SINGLE‐ARM, OPEN‐LABEL, MULTICENTER PHASE II STUDY
  di: J. Liang, et al.
  Pubblicazione: (2025)
• 112 | PHASE I STUDY OF SPLIT‐COURSE BRIDGING RADIOTHERAPY (SC‐BRT) PRIOR TO CAR T‐CELL THERAPY FOR RELAPSED/REFRACTORY B‐CELL LYMPHOMAS
  di: B. S. Imber, et al.
  Pubblicazione: (2025)
• 855 | A PHASE 3 RANDOMIZED TRIAL: DUVELISIB VERSUS INVESTIGATOR CHOICE (GEMCITABINE OR BENDAMUSTINE) IN RELAPSED/REFRACTORY NODAL T‐CELL LYMPHOMA WITH T‐FOLLICULAR HELPER PHENOTYPE
  di: K. Cwynarski, et al.
  Pubblicazione: (2025)